Polyrizon initiates human study for NASARIX allergy blocker
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- S&P 500, Nasdaq fall as investors juggle earnings, Mideast risks and tariffs
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil retreats from above $100, still set for weekly rise on Middle East escalation
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- Meta’s new seller app hits eBay where it hurts most
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
June 15, 2026 8:05 AM EDTNew performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX allergy blockers protective barrier function
Raanana, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the Company or Polyrizon), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the execution of an agreement with a leading, internationally recognized European university medical center, alongside a contract with a specialized clinical research organization (CRO), to conduct a human study as part of its verification and validation (V&V)... More
